Selinexor – pro

Selinexor (KPT-330) is a first in class SINE XPO1 antagonist, being evaluated in multiple later stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Our SINE compounds were the first oral XPO1 inhibitors in clinical development.Approval in this case is being sought for compassionate use.
POVIO ® (selinexor) is a prescription medicine approved: in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma (MM) who have received at least one prior therapy. Pomalidomide and dexamaethsone is highly active and represents a good bridging therapy to the CAR-T therapy. It is included in NCCN MYEL-G, 4 2022

  • Rosebeck S, Kandarpa M, Alonge MM, et al. Effects of inhibition of XPO1/CRM1-dependent nuclear export by selinexor (KPT- 330), alone and in combination with carfilzomib (cfz), on apoptosis and autophagy in multiple myeloma (MM). Blood. 2013;122(21):279.

    • Bahlis N, Chen C, Sebag M, et al. A phase 1B/2 study of selinexor in combination with backbone therapies for treatment of relapsed/refractory multiple myeloma. Paper presented at: 21st Congress of the European Hematology Association; June 9-12 2016; Copenhagen, Denmark.
    Prescribing Information, Xpovio 2022
    Darrell J White, et al, Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma. Blood (2021) 138 (Supplement 1): 2748.

  • Bahlis N, Chen C, Sebag M, et al. A phase 1B/2 study of selinexor in combination with backbone therapies for treatment of relapsed/refractory multiple myeloma. Paper presented at: 21st Congress of the European Hematology Association; June 9-12 2016; Copenhagen, Denmark.

    • Xpovio Prescribing INfromation 2022

    Categories

    Blog Archives